GlassScriptPhysician profile
Jonathon Troy Jackson
NPI 1366804163
$4,542.45
in general payments reported to CMS, 2019-2025
35 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $421 · 2021: $1,311 · 2022: $1,134 · 2023: $1,257 · 2024: $80.71 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.66 | 2020-2025 | |
| Lilly USA, LLC | $511.11 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.31 | 2020-2025 | Xifaxan |
| Preventric Diagnostics, INC. | $368.38 | 2021-2022 | |
| Novo Nordisk INC | $334.72 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $332.34 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $285.17 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $251.72 | 2019-2023 | |
| Amgen INC. | $183.65 | 2020-2023 | Prolia, Evenity, Otezla |
| Pfizer INC. | $155.94 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.71 | 2020-2022 | |
| Antares Pharma, INC. | $81.32 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $72.90 | 2021-2023 | |
| Dexcom, INC. | $71.09 | 2022-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.44 | 2022-2023 | Octrode |
| Halozyme INC | $52.80 | 2023 | |
| Corium, LLC | $49.46 | 2023 | Azstarys |
| Organon LLC | $41.85 | 2022-2025 | Nexplanon |
| Insulet Corporation | $40.53 | 2019 | |
| Neos Therapeutics, LP | $38.26 | 2020-2021 | |
| Treace Medical Concepts, INC. | $36.28 | 2022 | |
| Astellas Pharma US INC | $35.55 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $30.00 | 2021-2022 | |
| Exact Sciences Corporation | $28.61 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medtronic, INC. | $24.99 | 2025 | Inceptiv |
| Vanda Pharmaceuticals INC. | $23.36 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.74 | 2021 | |
| Tolmar, INC. | $17.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.71 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.27 | 2021 | |
| Amarin Pharma, INC. | $14.93 | 2020 | |
| Eisai INC. | $14.17 | 2021 | |
| Allergan, INC. | $13.58 | 2020 | |
| Ibsa Pharma INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.